679 related articles for article (PubMed ID: 26803277)
1. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
[TBL] [Abstract][Full Text] [Related]
3. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC;
Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
5. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial.
Davies JC; Wainwright CE; Sawicki GS; Higgins MN; Campbell D; Harris C; Panorchan P; Haseltine E; Tian S; Rosenfeld M
Am J Respir Crit Care Med; 2021 Mar; 203(5):585-593. PubMed ID: 33023304
[No Abstract] [Full Text] [Related]
6. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA
Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000
[TBL] [Abstract][Full Text] [Related]
7. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
Rosenfeld M; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Chilvers M; Higgins M; Tian S; Cooke J; Davies JC;
J Cyst Fibros; 2019 Nov; 18(6):838-843. PubMed ID: 31053538
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
[TBL] [Abstract][Full Text] [Related]
9. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
10. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ; MacGregor G; Azevedo P; Indihar V; Keating C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Rubenstein RC; Taylor-Cousar JL; Tullis E; Yonker LM; Chu C; Lam AP; Nair N; Sosnay PR; Tian S; Van Goor F; Viswanathan L; Waltz D; Wang LT; Xi Y; Billings J; Horsley A; ;
Lancet Respir Med; 2023 Jun; 11(6):550-562. PubMed ID: 36842446
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for
Rayment JH; Asfour F; Rosenfeld M; Higgins M; Liu L; Mascia M; Paz-Diaz H; Tian S; Zahigian R; McColley SA
Am J Respir Crit Care Med; 2022 Nov; 206(10):1239-1247. PubMed ID: 35771568
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
17. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
[TBL] [Abstract][Full Text] [Related]
19. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
Walker S; Flume P; McNamara J; Solomon M; Chilvers M; Chmiel J; Harris RS; Haseltine E; Stiles D; Li C; Ahluwalia N; Zhou H; Owen CA; Sawicki G;
J Cyst Fibros; 2019 Sep; 18(5):708-713. PubMed ID: 31253540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]